Skip to main content

Advertisement

SpringerLink
Log in

Kein Vorteil für die Gesamtgruppe der Mammakarzinompatientinnen durch adjuvante Therapie mit Zoledronsäure

No advantage for the overall group of breast cancer patients undergoing adjuvant therapy with zoledronic acid

  • Literatur kommentiert
  • Published:
Strahlentherapie und Onkologie Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Yan T, Yin W, Zhou Q et al (2012) The efficacy of zoledronic acid in breast cancer adjuvant therapy: a meta-analysis of randomised controlled trials. Eur J Cancer 48:187–195

    Article  PubMed  CAS  Google Scholar 

  2. Aft R, Naughton M, Trinkaus K et al (2010) Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomized, phase II trial. Lancet Oncol 11:421–428

    Article  PubMed  CAS  Google Scholar 

  3. Neville-Webbe HL, Coleman RE, Holen I (2010) Combined effects of bisphosphonate, zoledronic acid and aromatase inhibitor letrozol on breast cancer cells in vitro: evidence of synergistic interaction. Br J Cancer 102:1010–1017

    Article  PubMed  CAS  Google Scholar 

  4. Interdisziplinäre S3-Leitlinie für die Diagnostik, Therapie und Nachsorge des Mammakarzinoms. Langversion 3.0, Aktualisierung 2012. AWMF-Register-Nummer: 302–0450L

  5. Guidelines of the AGO Breast Committee 2012, Version 1. Herausgegeben von der Kommission Mamma der AGO (vertreten durch: Anton Scharl) Update 2012. AGO Breast Committee. Deutsche Version 2012 vs1. http://www.ago-online.org/Leitlinien

Download references

Author information

Authors and Affiliations

  1. MVZ Radioonkologie, Universitätsklinikum Tübingen, Hoppe-Seyler-Str. 3, 72076, Tübingen, Deutschland

    R. Souchon

Authors
  1. R. Souchon
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to R. Souchon.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Souchon, R. Kein Vorteil für die Gesamtgruppe der Mammakarzinompatientinnen durch adjuvante Therapie mit Zoledronsäure. Strahlenther Onkol 188, 1157–1158 (2012). https://doi.org/10.1007/s00066-012-0252-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00066-012-0252-7

Search

Navigation